{"DataElement":{"publicId":"2923338","version":"1","preferredName":"Temporomandibular Joint Disorder Pain Treatment Muscle Relaxant Prescription Administered Type","preferredDefinition":"the type of prescribed muscle relaxant treatment for pain from any condition affecting the anatomic and functional characteristics of the temporomandibular joint.","longName":"TMJD_P_TX_MR_P_A_TP","context":"NIDCR","contextVersion":"1","DataElementConcept":{"publicId":"2903837","version":"1","preferredName":"Temporomandibular Joint Disorder Pain Treatment Muscle Relaxant Prescription Administered","preferredDefinition":"information related to prescribed muscle relaxant treatment for pain from any condition affecting the anatomic and functional characteristics of the temporomandibular joint.","longName":"TMJD_PAI_TX_MR_P_AD","context":"NIDCR","contextVersion":"1","ObjectClass":{"publicId":"2862211","version":"1","preferredName":"Temporomandibular Joint Disorder Pain Therapy","preferredDefinition":"Any condition affecting the anatomic and functional characteristics of the temporomandibular joint.:An unpleasant sensation induced by noxious stimuli and generally received by specialized nerve endings.:An action or administration of therapeutic agents to produce an effect that is intended to alter the course of a pathologic process.","longName":"C63709:C3303:C15368","context":"NCIP","contextVersion":"1","Concepts":[{"longName":"Temporomandibular Joint Disorder","conceptCode":"C63709","definition":"A disorder that affects the masticatory muscles and temporomandibular joint.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"No","displayOrder":"2"},{"longName":"Pain","conceptCode":"C3303","definition":"The sensation of discomfort, distress, or agony, resulting from the stimulation of specialized nerve endings.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"No","displayOrder":"1"},{"longName":"Therapy","conceptCode":"C15368","definition":"An action or administration of therapeutic agents to produce an effect that is intended to alter the course of a pathologic process.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"Yes","displayOrder":"0"}],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"68295BCC-97AD-8D2C-E040-BB89AD4314FA","latestVersionIndicator":"Yes","beginDate":"2009-04-22","endDate":null,"createdBy":"ALAIS","dateCreated":"2009-04-22","modifiedBy":"ONEDATA","dateModified":"2009-04-22","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"Property":{"publicId":"2903835","version":"1","preferredName":"Muscle Relaxant Preparation Prescription Administered","preferredDefinition":"Synthetic compounds or mixtures with muscle relaxant activity. A muscle relaxant preparation is used to prevent muscle spasms by inhibiting muscle contractions and to relief pain associated with the spasms.:A doctor's order for medicine or another intervention.:Given.","longName":"C29891:C28180:C25382","context":"NCIP","contextVersion":"1","Concepts":[{"longName":"Muscle Relaxant Preparation","conceptCode":"C29891","definition":"Synthetic compounds or mixtures with muscle relaxant activity. A muscle relaxant preparation is used to prevent muscle spasms by inhibiting muscle contractions and to relief pain associated with the spasms.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"No","displayOrder":"2"},{"longName":"Prescription","conceptCode":"C28180","definition":"A verbal or written order given by an authorized person instructing a patient to obtain and use a medical device, prescription or undergo a procedure.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"No","displayOrder":"1"},{"longName":"Administered","conceptCode":"C25382","definition":"The act of having given something (e.g., a medication or test).","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"Yes","displayOrder":"0"}],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"6CF21001-CF9E-76A9-E040-BB89AD437ABF","latestVersionIndicator":"Yes","beginDate":"2009-06-22","endDate":null,"createdBy":"ALAIS","dateCreated":"2009-06-22","modifiedBy":"ONEDATA","dateModified":"2009-06-22","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"ConceptualDomain":{"publicId":"2008538","version":"1","preferredName":"Therapies","preferredDefinition":"actions or administration of therapeutic agents to produce an effect that is intended to alter the course of a pathologic process (NCI).","longName":"TX","context":"CTEP","contextVersion":"2.31","origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"B214D04D-9F05-1CA5-E034-0003BA12F5E7","latestVersionIndicator":"Yes","beginDate":"2002-12-18","endDate":null,"createdBy":"MSUPLEY","dateCreated":"2002-12-18","modifiedBy":"SBR","dateModified":"2003-10-29","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":"PEARL CRF:Practitioners Engaged in Applied Research and Learning Network Case Report Form","workflowStatus":"RELEASED","registrationStatus":"Application","id":"6CF21001-CFAF-76A9-E040-BB89AD437ABF","latestVersionIndicator":"Yes","beginDate":"2009-06-22","endDate":null,"createdBy":"ALAIS","dateCreated":"2009-06-22","modifiedBy":"SBR","dateModified":"2016-06-06","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"ValueDomain":{"publicId":"2923332","version":"1","preferredName":"Muscle Relaxant Medication Administered Type","preferredDefinition":"the type of muscle relaxant medication administered.","longName":"MU_REL_MED_ADM_TP","context":"NIDCR","contextVersion":"1","type":"Enumerated","dataType":"CHARACTER","minLength":null,"maxLength":"50","minValue":null,"maxValue":null,"decimalPlace":null,"PermissibleValues":[{"value":"None","valueDescription":"None at all","ValueMeaning":{"publicId":"2574138","version":"1","preferredName":"None at all","longName":"2574138","preferredDefinition":"No person or thing, nobody, not any.","context":"NCIP","contextVersion":"1","Concepts":[{"longName":"None","conceptCode":"C41132","definition":"No person or thing, nobody, not any.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"Yes","displayOrder":"0"}],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"2509CE87-EEA7-5C23-E044-0003BA3F9857","latestVersionIndicator":"Yes","beginDate":"2003-11-14","endDate":null,"createdBy":"SBREXT","dateCreated":"2003-11-14","modifiedBy":"CLOHNES","dateModified":"2022-08-12","changeDescription":null,"administrativeNotes":"8/12/22 added alt VM for Alliance cjl;","unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"6FB34A35-F6AF-0250-E040-BB89AD4308FF","beginDate":"2009-07-27","endDate":null,"createdBy":"ALAIS","dateCreated":"2009-07-27","modifiedBy":"ONEDATA","dateModified":"2009-07-27","deletedIndicator":"No"},{"value":"Other","valueDescription":"Other","ValueMeaning":{"publicId":"2559653","version":"1","preferredName":"Other","longName":"2559653","preferredDefinition":"Different than the one(s) previously specified or mentioned.","context":"NCIP","contextVersion":"1","Concepts":[{"longName":"Other","conceptCode":"C17649","definition":"Different than the one(s) previously specified or mentioned.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"Yes","displayOrder":"0"}],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"2509CE87-B612-5C23-E044-0003BA3F9857","latestVersionIndicator":"Yes","beginDate":"2002-02-13","endDate":null,"createdBy":"SBR","dateCreated":"2002-02-13","modifiedBy":"GDEEN","dateModified":"2023-12-28","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"6FB34A35-F6B9-0250-E040-BB89AD4308FF","beginDate":"2009-07-27","endDate":null,"createdBy":"ALAIS","dateCreated":"2009-07-27","modifiedBy":"ONEDATA","dateModified":"2009-07-27","deletedIndicator":"No"},{"value":"Orphenadrine","valueDescription":"Orphenadrine","ValueMeaning":{"publicId":"2923334","version":"1","preferredName":"Orphenadrine","longName":"2923334","preferredDefinition":"A muscarinic antagonist with muscle relaxant activity. Although the mechanism of action has not been determined, orphenadrine appears to block muscarinic acetylcholine receptors as well as N-methyl-D-aspartate (NMDA) receptors in the central nervous system (CNS). This may interfere with the transmission of nerve impulses from the spinal cord to the muscles and may help relax muscles. In addition, orphenadrine exerts antagonistic effects on histamine H1 receptors.","context":"NCIP","contextVersion":"1","Concepts":[{"longName":"Orphenadrine","conceptCode":"C61868","definition":"A muscarinic antagonist with muscle relaxant activity. Although the mechanism of action has not been determined, orphenadrine appears to block muscarinic acetylcholine receptors as well as N-methyl-D-aspartate (NMDA) receptors in the central nervous system (CNS). This may interfere with the transmission of nerve impulses from the spinal cord to the muscles and may help relax muscles. In addition, orphenadrine exerts antagonistic effects on histamine H1 receptors.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"Yes","displayOrder":"0"}],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"6FB34A35-F6C6-0250-E040-BB89AD4308FF","latestVersionIndicator":"Yes","beginDate":"2009-07-27","endDate":null,"createdBy":"ALAIS","dateCreated":"2009-07-27","modifiedBy":"KUMMEROA","dateModified":"2022-03-30","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"6FB34A35-F6DF-0250-E040-BB89AD4308FF","beginDate":"2009-07-27","endDate":null,"createdBy":"ALAIS","dateCreated":"2009-07-27","modifiedBy":"ONEDATA","dateModified":"2009-07-27","deletedIndicator":"No"},{"value":"Methocarbamol","valueDescription":"Methocarbamol","ValueMeaning":{"publicId":"2578268","version":"1","preferredName":"Methocarbamol","longName":"2578268","preferredDefinition":"A carbamate with centrally acting muscle relaxant properties. Though the exact mechanism of action of methocarbamol was not established, it's postulated to be via a mechanism similar of carbamate, inhibition of acetylcholinesterase at synapses in the autonomic nervous system, neuromuscular junction, and central nervous system. Methocarbamol has no direct effect on the contractile mechanism of striated muscle, the motor end plate or the nerve fiber.","context":"NCIP","contextVersion":"1","Concepts":[{"longName":"Methocarbamol","conceptCode":"C29252","definition":"A carbamate with centrally acting muscle relaxant properties. Though the exact mechanism of action of methocarbamol was not established, it's postulated to be via a mechanism similar of carbamate, inhibition of acetylcholinesterase at synapses in the autonomic nervous system, neuromuscular junction, and central nervous system. Methocarbamol has no direct effect on the contractile mechanism of striated muscle, the motor end plate or the nerve fiber.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"Yes","displayOrder":"0"}],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"2509CE87-FEC9-5C23-E044-0003BA3F9857","latestVersionIndicator":"Yes","beginDate":"2006-03-14","endDate":null,"createdBy":"REEVESD","dateCreated":"2006-03-14","modifiedBy":"ONEDATA","dateModified":"2006-03-14","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"6FB34A35-F6E9-0250-E040-BB89AD4308FF","beginDate":"2009-07-27","endDate":null,"createdBy":"ALAIS","dateCreated":"2009-07-27","modifiedBy":"ONEDATA","dateModified":"2009-07-27","deletedIndicator":"No"},{"value":"Metaxalone","valueDescription":"Metaxalone","ValueMeaning":{"publicId":"2923336","version":"1","preferredName":"Metaxalone","longName":"2923336","preferredDefinition":"An oxazolidinone with centrally-acting skeletal muscle relaxant properties. Although the exact mechanism through which metaxalone exerts its effect is largely unknown, it might be due to general central nervous system (CNS) depression. Metaxalone has no direct effect on the contractile mechanisms of striated muscle, the motor end plate, or the nerve fiber.","context":"NCIP","contextVersion":"1","Concepts":[{"longName":"Metaxalone","conceptCode":"C47606","definition":"An oxazolidinone with centrally-acting skeletal muscle relaxant properties. Although the exact mechanism through which metaxalone exerts its effect is largely unknown, it might be due to general central nervous system (CNS) depression. Metaxalone has no direct effect on the contractile mechanisms of striated muscle, the motor end plate, or the nerve fiber.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"Yes","displayOrder":"0"}],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"6FB34A35-F6F6-0250-E040-BB89AD4308FF","latestVersionIndicator":"Yes","beginDate":"2009-07-27","endDate":null,"createdBy":"ALAIS","dateCreated":"2009-07-27","modifiedBy":"SBR","dateModified":"2018-01-19","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"6FB34A35-F70F-0250-E040-BB89AD4308FF","beginDate":"2009-07-27","endDate":null,"createdBy":"ALAIS","dateCreated":"2009-07-27","modifiedBy":"ONEDATA","dateModified":"2009-07-27","deletedIndicator":"No"},{"value":"Diazepam","valueDescription":"Diazepam","ValueMeaning":{"publicId":"2576102","version":"1","preferredName":"Diazepam","longName":"2576102","preferredDefinition":"A benzodiazepine derivative with anti-anxiety, sedative, hypnotic and anticonvulsant properties. Diazepam potentiates the inhibitory activities of gamma-aminobutyric acid (GABA) by binding to the GABA receptor, located in the limbic system and the hypothalamus. This increases the frequency of chloride channel opening, allowing the flow of chloride ions into the neuron and ultimately leading to membrane hyperpolarization and a decrease in neuronal excitability.","context":"NCIP","contextVersion":"1","Concepts":[{"longName":"Diazepam","conceptCode":"C28982","definition":"A benzodiazepine derivative with anti-anxiety, sedative, hypnotic and anticonvulsant properties. Diazepam potentiates the inhibitory activities of gamma-aminobutyric acid (GABA) by binding to the GABA receptor, located in the limbic system and the hypothalamus. This increases the frequency of chloride channel opening, allowing the flow of chloride ions into the neuron and ultimately leading to membrane hyperpolarization and a decrease in neuronal excitability.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"Yes","displayOrder":"0"}],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"2509CE87-F653-5C23-E044-0003BA3F9857","latestVersionIndicator":"Yes","beginDate":"2005-08-30","endDate":null,"createdBy":"REEVESD","dateCreated":"2005-08-30","modifiedBy":"COOPERM","dateModified":"2019-08-05","changeDescription":"Added definition to concept. mc 8/5/19","administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"6FB34A35-F719-0250-E040-BB89AD4308FF","beginDate":"2009-07-27","endDate":null,"createdBy":"ALAIS","dateCreated":"2009-07-27","modifiedBy":"ONEDATA","dateModified":"2009-07-27","deletedIndicator":"No"},{"value":"Clonazepam","valueDescription":"Clonazepam","ValueMeaning":{"publicId":"2577827","version":"1","preferredName":"Clonazepam","longName":"2577827","preferredDefinition":"A synthetic benzodiazepine derivative used for myotonic or atonic seizures, absence seizures, and photosensitive epilepsy, anticonvulsant Clonazepam appears to enhance gamma-aminobutyric acid receptor responses, although its mechanism of action is not clearly understood. It is seldom effective in generalized tonic-clonic or partial seizures. (NCI04)","context":"NCIP","contextVersion":"1","Concepts":[{"longName":"Clonazepam","conceptCode":"C28935","definition":"A synthetic benzodiazepine derivative used for myotonic or atonic seizures, absence seizures, and photosensitive epilepsy, anticonvulsant Clonazepam appears to enhance gamma-aminobutyric acid receptor responses, although its mechanism of action is not clearly understood. It is seldom effective in generalized tonic-clonic or partial seizures. (NCI04)","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"Yes","displayOrder":"0"}],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"2509CE87-FD10-5C23-E044-0003BA3F9857","latestVersionIndicator":"Yes","beginDate":"2005-08-29","endDate":null,"createdBy":"REEVESD","dateCreated":"2005-08-29","modifiedBy":"REEVESD","dateModified":"2006-02-21","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"6FB34A35-F723-0250-E040-BB89AD4308FF","beginDate":"2009-07-27","endDate":null,"createdBy":"ALAIS","dateCreated":"2009-07-27","modifiedBy":"ONEDATA","dateModified":"2009-07-27","deletedIndicator":"No"},{"value":"Cyclobenzaprine","valueDescription":"Cyclobenzaprine","ValueMeaning":{"publicId":"2576082","version":"1","preferredName":"Cyclobenzaprine","longName":"2576082v1.00","preferredDefinition":"A centrally acting skeletal muscle relaxant with antidepressant activity. The exact mechanism of action of cyclobenzaprine has not been fully determined, but this drug seems to primarily act at the brain stem to reduce tonic somatic motor activity, influencing both gamma and alpha motor neurons leading to a reduction in muscle spasms.","context":"NCIP","contextVersion":"1","Concepts":[{"longName":"Cyclobenzaprine","conceptCode":"C28947","definition":"A centrally acting skeletal muscle relaxant with antidepressant activity. The exact mechanism of action of cyclobenzaprine has not been fully determined, but this drug seems to primarily act at the brain stem to reduce tonic somatic motor activity, influencing both gamma and alpha motor neurons leading to a reduction in muscle spasms.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"Yes","displayOrder":"0"}],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"2509CE87-F63F-5C23-E044-0003BA3F9857","latestVersionIndicator":"Yes","beginDate":"2005-08-30","endDate":null,"createdBy":"REEVESD","dateCreated":"2005-08-30","modifiedBy":"KUMMEROA","dateModified":"2023-08-30","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"6FB34A35-F72D-0250-E040-BB89AD4308FF","beginDate":"2009-07-27","endDate":null,"createdBy":"ALAIS","dateCreated":"2009-07-27","modifiedBy":"ONEDATA","dateModified":"2009-07-27","deletedIndicator":"No"}],"ConceptualDomain":{"publicId":"2008538","version":"1","preferredName":"Therapies","preferredDefinition":"actions or administration of therapeutic agents to produce an effect that is intended to alter the course of a pathologic process (NCI).","longName":"TX","context":"CTEP","contextVersion":"2.31","origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"B214D04D-9F05-1CA5-E034-0003BA12F5E7","latestVersionIndicator":"Yes","beginDate":"2002-12-18","endDate":null,"createdBy":"MSUPLEY","dateCreated":"2002-12-18","modifiedBy":"SBR","dateModified":"2003-10-29","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"RepresentationTerm":{"publicId":"2234813","version":"1","preferredName":"Type","preferredDefinition":"Type; a subdivision of a particular kind of thing.","longName":"C25284","context":"NCIP","contextVersion":"1","Concepts":[{"longName":"Type","conceptCode":"C25284","definition":"Something distinguishable as an identifiable class based on common qualities.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"Yes","displayOrder":"0"}],"origin":"NCI Thesaurus","workflowStatus":"RELEASED","registrationStatus":"Standard","id":"F970CDF6-F90E-21D3-E034-0003BA3F9857","latestVersionIndicator":"Yes","beginDate":"2005-06-14","endDate":null,"createdBy":"CAMPBELB","dateCreated":"2005-06-14","modifiedBy":"SBR","dateModified":"2005-09-08","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":"PEARL CRF:Practitioners Engaged in Applied Research and Learning Network Case Report Form","workflowStatus":"RELEASED","registrationStatus":"Application","id":"6FB34A35-F69B-0250-E040-BB89AD4308FF","latestVersionIndicator":"Yes","beginDate":"2009-07-27","endDate":null,"createdBy":"ALAIS","dateCreated":"2009-07-27","modifiedBy":"KUMMEROA","dateModified":"2023-08-30","changeDescription":null,"administrativeNotes":"2023.8.30 Updated PV def for 'No Value Exists'. ak","unresolvedIssues":null,"deletedIndicator":"No"},"ClassificationSchemes":[{"publicId":"2857180","version":"1","longName":"Type of Category","context":"NIDCR","ClassificationSchemeItems":[{"publicId":"2812084","version":"1","longName":"Diagnostic","context":"NIDCR"},{"publicId":"2812085","version":"1","longName":"Preventive","context":"NIDCR"},{"publicId":"2812094","version":"1","longName":"Orthodontics","context":"NIDCR"}]},{"publicId":"2857182","version":"1","longName":"Protocol Forms","context":"NIDCR","ClassificationSchemeItems":[{"publicId":"2812041","version":"1","longName":"NIDCR","context":"NIDCR"}]}],"AlternateNames":[],"ReferenceDocuments":[{"name":"The muscle relaxant(s) that y","type":"Preferred Question Text","description":"The muscle relaxant(s) that you prefer to prescribe","url":null,"context":"NIDCR"}],"origin":"PEARL CRF:Practitioners Engaged in Applied Research and Learning Network Case Report Form","workflowStatus":"RELEASED","registrationStatus":"Qualified","id":"6FB34A35-F737-0250-E040-BB89AD4308FF","latestVersionIndicator":"Yes","beginDate":"2009-07-27","endDate":null,"createdBy":"ALAIS","dateCreated":"2009-07-27","modifiedBy":"ALAIS","dateModified":"2011-08-12","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"}}